Treats steroid responsive inflammatory conditions of the palpebral and bulbar…. Sold as Flarex. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Fluorometholone Acetate (sold as Flarex), first approved Feb 11, 1986, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Flarex | Part D | $1.0M | -62% | 4,390 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Vevye + Flarex Combination Therapy for Dry EyeDry Eye · Canyon City Eyecare | Phase 4 | Enrolling by invitation | Apr 28, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Feb 11, 1986 | FlarexNDA 19079 · New active ingredient | Harrow Eye | 27 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
